Immunovia AB (publ) IMMNOV
This picture changes. Follow Immunovia AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow Immunovia AB (publ) freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 7 Aug 2026
General analysis — not personal advice.
NEUTRAL
4/10
Confidence
Wait/hold a small watch position until clear volume growth and improved coverage signals emerge.
The Q2 report confirms low revenue growth and high burn rate, keeping the signal at review until clear signs of Medicare progress and volume growth appear.
Market sentiment
6/10
↑
Trend: Improving
Sentiment has improved toward neutral following the published AFFIRM results and new performance data that strengthen the reimbursement narrative, though investors remain focused on very low revenues, potential funding needs, and US execution risk.
Price context
The share trades at an extremely low level around 0.182 SEK after the report, reflecting market concern over liquidity but leaving room for leverage on positive Medicare news.
Risk assessment
9/10
Dilution:
Medium
Cash of 34.9 MSEK and quarterly burn around 20 MSEK means capital may be required during 2026.
Jurisdiction:
Low
Sweden/US with stable regulatory frameworks
Execution:
High
Difficult U.S. commercialization and reimbursement pathway
Cash flow:
9 mo
Recent changes
- The report confirms low revenue and high burn, increasing focus on financing needs.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (4) — follow the company freeAbout the company
Immunovia AB (publ) develops and commercializes PancreaSure, a blood test aimed at early detection of pancreatic cancer in high-risk patients. The company is in an early U.S. commercialization phase with very low revenues and continued cash burn. Key value drivers are reimbursement/coverage, state-by-state regulatory rollout, and clinical utility evidence.
Sector:
Cancer diagnostics (blood test for pancreatic cancer)
Type:
Biotech
Next report
5 Nov 2026
Q3
Catalysts
Unknown
ASSURE study initiated
High
Unknown
Planned Medicare application
High
Unknown
Regulatory coverage in 49 of 50 states
Medium
Horizon:
Bull case
Confirmed Medicare application could quickly broaden sales and trigger a price reaction from low valuation.
Bear case
Lack of Medicare application news combined with dwindling cash risks increasing financing concerns.
Signal rationale (informational)
The Q2 report confirms low revenue growth and high burn rate, keeping the signal at review until clear signs of Medicare progress and volume growth appear.
Recent news
- Q2 report was published on 6 August showing revenue of 0.4 MSEK, operating loss of 22.8 MSEK and cash of 34.9 MSEK, confirming the need for financing ahead of Q4.
Price & valuation
Last close
SEK 0.16
1 week
-11.2 %
3 months
-13.7 %
Exchange
Stockholm
Type
Biotech
Sector
Cancer diagnostics (blood test for pancreatic cancer)
This picture changes. Follow Immunovia AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.